Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Cash from Financing Activities (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Cash from Financing Activities data on record, last reported at $6.4 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 36.83% year-over-year to $6.4 million; the TTM value through Sep 2025 reached $19.8 million, up 130.5%, while the annual FY2024 figure was $4.6 million, 11.93% up from the prior year.
  • Cash from Financing Activities reached $6.4 million in Q3 2025 per MBRX's latest filing, up from $5.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $74.7 million in Q1 2021 and bottomed at -$25000.0 in Q2 2024.
  • Average Cash from Financing Activities over 5 years is $7.4 million, with a median of $95000.0 recorded in 2023.
  • The widest YoY moves for Cash from Financing Activities: up 116575.0% in 2024, down 151.02% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$24000.0 in 2021, then soared by 54.17% to -$11000.0 in 2022, then skyrocketed by 36054.55% to $4.0 million in 2023, then plummeted by 99.97% to $1000.0 in 2024, then surged by 637400.0% to $6.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $6.4 million in Q3 2025, $5.4 million in Q2 2025, and $8.0 million in Q1 2025.